3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 12, 2019 | Post-IPO Equity | Fr15M | 1 | Numab | — | Detail |
Jun 12, 2015 | IPO | — | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 20, 2019
GenSight Biologics
|
Post-IPO Debt | €15M | Biotechnology | — |
Dec 12, 2019
Numab
|
Series B | Fr22M | Biopharma | — |
Oct 21, 2019
Verseau Therapeutics
|
Series Unknown | $50M | Biotechnology | — |
May 2, 2018
Refuge Biotechnologies
|
Series B | $25M | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Numab | Yes | Post-IPO Equity |
3sbio has had 1 exits. 3sbio most notable exits include GenSight Biologics
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jul 15, 2016 | GenSight Biologics | IPO | Biotechnology | Detail |
3sbio has acquired 3 organizations. Their most recent acquisition was Sirton Pharmaceuticals on Jan 26, 2015. They acquired Sirton Pharmaceuticals for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jan 26, 2015
Sirton Pharmaceuticals
|
Manufacturing | acquisition | — | Detail |
Jul 24, 2015
Zhejiang Wansheng Pharmaceutical
|
Biotechnology | acquisition | $ 85M | Detail |
Sep 3, 2017
Therapure Biopharma
|
Manufacturing | acquisition | $ 290M | Detail |